Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Laser beats brachytherapy for restenosis:

This article was originally published in Clinica

Executive Summary

Data from a European study have revealed that treating in stent restenosis with aggressive excimer laser debulking produces lower restenosis rates than brachytherapy. Laser debulking, using Spectranetics' CVX-300 excimer laser, resulted in a low binary stenosis rate of 20% and target lesion revascularisation rate of 17%, according to data published in the American Journal of Cardiology (July 1). In stent restenosis tissue is suitable for laser ablation as it is highly cellular, soft and free of calcifications, says the Colorado Springs, Colorado firm.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT067537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel